
    
      We proposed a bicentric study cohort of obese patients (BMI > 40 kg/m2) treated by 1 day
      injection of Fondaparinux 2.5 mg after bypass surgery. Anti-Xa activity of Fondaparinux will
      be measured 4 times during hospitalisation for each patient to realise a pharmacokinetic
      modelisation of Fondaparinux. Haemorrhage and thromboembolics events will be collected.
    
  